Limited effectiveness with a 10-day bismuth-containing quadruple therapy (Pylera®) in third-line recue treatment for Helicobacter pylori infection. A real-life multicenter study
32 Ciencias Médicas
Fecha de publicación
Wiley Online Library
Rodriguez de Santiago, E., Martín de Argila de Prados, C., Marcos Prieto, H. M., Turrión, M. A. J., Barreiro Alonso, E., Flores de Miguel, A., de la Coba Ortiz, C., Rodríguez Escaja, C., Pérez Álvarez, G., Ferre Aracil, C., Aguilera Castro, L., García García de Paredes, A., Rodríguez Pérez, A., & Albillos Martínez, A. (2017). Limited effectiveness with a 10-day bismuth-containing quadruple therapy (Pylera®) in third-line recue treatment for Helicobacter pylori infection. A real-life multicenter study. Helicobacter, 22(5), 12423. https://doi.org/10.1111/hel.12423
[EN]To assess the effectiveness, safety, and tolerance of Pylera® as a third-line in clinical practice.This was a multicenter, observational, prospective database study in four Spanish hospitals. Consecutive H. pylori-infected individuals treated with Pylera® and a proton-pump inhibitor (PPI) were invited to participate if they had failed to respond to PPI-clarithromycin-amoxicillin as first-line and to levofloxacinamoxicillin-PPI as second-line therapy. Eradication was tested 4-8 weeks after Pylera® using a C13-urea breath test. Treatment-related adverse effects (TRAEs) were assessed through a questionnaire and by reviewing databases.Of 103 subjects fulfilling the selection criteria, 101 were included in the intention-to-treat (ITT) analysis and 97 in the per-protocol (PP) analysis. In an area of high antibiotic resistance to H. pylori, 10-day Pylera® plus double-dose PPI emerged as an alternative as third-line therapy, although not achieving optimal eradication rates.
Versión del editor
Files in this item